FI63566C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara dibenso(d g)(1,3,6)dioxazocin-derivat och av deras fysiologiskt godtagbara syraadditionssalter - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara dibenso(d g)(1,3,6)dioxazocin-derivat och av deras fysiologiskt godtagbara syraadditionssalter Download PDFInfo
- Publication number
- FI63566C FI63566C FI782340A FI782340A FI63566C FI 63566 C FI63566 C FI 63566C FI 782340 A FI782340 A FI 782340A FI 782340 A FI782340 A FI 782340A FI 63566 C FI63566 C FI 63566C
- Authority
- FI
- Finland
- Prior art keywords
- formula
- alkylene
- dibenzo
- chloro
- derivatives
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 2
- SKUQZRMWNACBLW-UHFFFAOYSA-N 4h-1,3,6-dioxazocine Chemical class C1OCC=NC=CO1 SKUQZRMWNACBLW-UHFFFAOYSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- -1 aminoalkyl halide Chemical class 0.000 claims description 36
- 239000000460 chlorine Substances 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 34
- 229910052801 chlorine Inorganic materials 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical group CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 229910052757 nitrogen Inorganic materials 0.000 description 22
- 239000000203 mixture Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 238000002844 melting Methods 0.000 description 15
- 230000008018 melting Effects 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 14
- 239000008096 xylene Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 11
- 239000002585 base Substances 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 230000003444 anaesthetic effect Effects 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 229960004194 lidocaine Drugs 0.000 description 6
- 239000003589 local anesthetic agent Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical class [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 229960001032 trihexyphenidyl Drugs 0.000 description 3
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 2
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000007281 aminoalkylation reaction Methods 0.000 description 2
- 230000000648 anti-parkinson Effects 0.000 description 2
- 239000000939 antiparkinson agent Substances 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- WNRWEBKEQARBKV-UHFFFAOYSA-N 1-(2-chloroethyl)piperidine Chemical compound ClCCN1CCCCC1 WNRWEBKEQARBKV-UHFFFAOYSA-N 0.000 description 1
- JSUAJTLKVREZHV-UHFFFAOYSA-N 1-[4-(1-pyrrolidinyl)but-2-ynyl]pyrrolidine Chemical compound C1CCCN1CC#CCN1CCCC1 JSUAJTLKVREZHV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UGXACBBAXFABGT-UHFFFAOYSA-N 3-chloro-n,n,2-trimethylpropan-1-amine Chemical compound ClCC(C)CN(C)C UGXACBBAXFABGT-UHFFFAOYSA-N 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- JCSGFQAJKZZAKU-UHFFFAOYSA-N Cl.O1NOCC=C1 Chemical compound Cl.O1NOCC=C1 JCSGFQAJKZZAKU-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical class [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- MNPXCHCSWCJIDS-UHFFFAOYSA-N dioxazocine Chemical class C1=CC=NOOC=C1 MNPXCHCSWCJIDS-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- YQWYULJVRNJNPN-UHFFFAOYSA-N n-[2-[(2-bromo-4-chlorophenoxy)methoxy]-5-chlorophenyl]formamide Chemical compound BrC1=CC(Cl)=CC=C1OCOC1=CC=C(Cl)C=C1NC=O YQWYULJVRNJNPN-UHFFFAOYSA-N 0.000 description 1
- LCKDAKQVVWCHNJ-UHFFFAOYSA-N n-[2-[(2-bromophenoxy)methoxy]-5-chlorophenyl]formamide Chemical compound O=CNC1=CC(Cl)=CC=C1OCOC1=CC=CC=C1Br LCKDAKQVVWCHNJ-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU77EE2515A HU174126B (hu) | 1977-08-02 | 1977-08-02 | Sposob poluchenija novykh proizvodnykh dibenzo-kvadratnaja skobka-d,g-kvadratnaja skobka zakryta-kvadratnaja skobka-1,3,6-kvadratnaja skobka zakryta-dioksazocina |
| HUEE002515 | 1977-08-02 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI782340A7 FI782340A7 (fi) | 1979-02-03 |
| FI63566B FI63566B (fi) | 1983-03-31 |
| FI63566C true FI63566C (fi) | 1983-07-11 |
Family
ID=10995738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI782340A FI63566C (fi) | 1977-08-02 | 1978-07-27 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara dibenso(d g)(1,3,6)dioxazocin-derivat och av deras fysiologiskt godtagbara syraadditionssalter |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US4208410A (cs) |
| AT (1) | AT363091B (cs) |
| AU (1) | AU517160B2 (cs) |
| CH (1) | CH635834A5 (cs) |
| CS (1) | CS207639B2 (cs) |
| DE (1) | DE2833892C2 (cs) |
| DK (1) | DK149889C (cs) |
| FI (1) | FI63566C (cs) |
| FR (1) | FR2399417A1 (cs) |
| GB (1) | GB2001980B (cs) |
| HU (1) | HU174126B (cs) |
| IT (1) | IT1097994B (cs) |
| NL (1) | NL187574C (cs) |
| PL (1) | PL111253B1 (cs) |
| SE (1) | SE441828B (cs) |
| SU (1) | SU810080A3 (cs) |
| YU (1) | YU40718B (cs) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU195491B (en) * | 1985-12-20 | 1988-05-30 | Egyt Gyogyszervegyeszeti Gyar | Process for production of optically active 2-chlor-12-/3-/dimethil-amin/-2-methil-prophil/-12h-dibenzol /d,g/ /1,3,6/-diaxazocine and medical compositions containing such compounds |
| HU198194B (en) * | 1986-12-30 | 1989-08-28 | Egyt Gyogyszervegyeszeti Gyar | Process for production of new derivatives of dioxazocin and medical compositions containing them |
| HU201318B (en) * | 1987-12-31 | 1990-10-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing dioxazoline derivatives and pharmaceutical compositions comprising same |
| US4966967A (en) * | 1989-09-15 | 1990-10-30 | Berlex Laboratories, Inc. | 3,4,5,6-tetrahydro-2H-1,7,4-benzodioxazonines as cardiovascular agents |
| DE69622415T2 (de) * | 1995-09-19 | 2003-03-06 | Novo Nordisk A/S, Bagsvaerd | 12H-Dibenzo[d,g][1,3]dioxocin Derivate |
| ES2194217T3 (es) * | 1996-10-04 | 2003-11-16 | Novo Nordisk As | Spperazinas 1,4-disustituidas. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3591604A (en) | 1968-10-01 | 1971-07-06 | Squibb & Sons Inc | Derivatives of dibenzoxazocine and dibenzthiazocine |
-
1977
- 1977-08-02 HU HU77EE2515A patent/HU174126B/hu not_active IP Right Cessation
-
1978
- 1978-07-17 AT AT0515578A patent/AT363091B/de not_active IP Right Cessation
- 1978-07-25 US US05/927,934 patent/US4208410A/en not_active Expired - Lifetime
- 1978-07-26 CS CS784965A patent/CS207639B2/cs unknown
- 1978-07-27 FI FI782340A patent/FI63566C/fi not_active IP Right Cessation
- 1978-07-27 FR FR7822207A patent/FR2399417A1/fr active Granted
- 1978-07-27 AU AU38396/78A patent/AU517160B2/en not_active Expired
- 1978-07-28 YU YU1821/78A patent/YU40718B/xx unknown
- 1978-07-28 SE SE7808234A patent/SE441828B/sv not_active IP Right Cessation
- 1978-07-31 PL PL1978208762A patent/PL111253B1/pl unknown
- 1978-07-31 CH CH818178A patent/CH635834A5/de not_active IP Right Cessation
- 1978-08-01 GB GB7831819A patent/GB2001980B/en not_active Expired
- 1978-08-01 DK DK340478A patent/DK149889C/da active
- 1978-08-01 IT IT26351/78A patent/IT1097994B/it active
- 1978-08-02 SU SU782644252A patent/SU810080A3/ru active
- 1978-08-02 DE DE2833892A patent/DE2833892C2/de not_active Expired
- 1978-08-02 NL NLAANVRAGE7808124,A patent/NL187574C/xx not_active IP Right Cessation
-
1979
- 1979-07-26 US US06/061,042 patent/US4229350A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| YU182178A (en) | 1983-02-28 |
| FR2399417B1 (cs) | 1981-02-13 |
| FI63566B (fi) | 1983-03-31 |
| AU517160B2 (en) | 1981-07-09 |
| GB2001980A (en) | 1979-02-14 |
| IT1097994B (it) | 1985-08-31 |
| SE7808234L (sv) | 1979-02-03 |
| PL208762A1 (pl) | 1979-06-04 |
| FR2399417A1 (fr) | 1979-03-02 |
| NL7808124A (nl) | 1979-02-06 |
| DE2833892C2 (de) | 1986-08-07 |
| CH635834A5 (de) | 1983-04-29 |
| US4229350A (en) | 1980-10-21 |
| US4208410A (en) | 1980-06-17 |
| NL187574C (nl) | 1991-11-18 |
| GB2001980B (en) | 1982-01-13 |
| FI782340A7 (fi) | 1979-02-03 |
| AT363091B (de) | 1981-07-10 |
| HU174126B (hu) | 1979-11-28 |
| CS207639B2 (en) | 1981-08-31 |
| DE2833892A1 (de) | 1979-02-22 |
| NL187574B (nl) | 1991-06-17 |
| SU810080A3 (ru) | 1981-02-28 |
| DK149889C (da) | 1987-04-27 |
| IT7826351A0 (it) | 1978-08-01 |
| SE441828B (sv) | 1985-11-11 |
| ATA515578A (de) | 1980-12-15 |
| AU3839678A (en) | 1980-01-31 |
| PL111253B1 (en) | 1980-08-30 |
| YU40718B (en) | 1986-04-30 |
| DK149889B (da) | 1986-10-20 |
| DK340478A (da) | 1979-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0314563A (ja) | 新規４―フルオロ安息香酸誘導体 | |
| JPH0647586B2 (ja) | １−ヘテロアリ−ル−４−〔（２．５−ピロリジンジオン−１−イル）アルキル〕ピペラジン誘導体 | |
| DK155796B (da) | Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenylmethyl)-1-piperazinyl)ethoxy)-eddikesyrer eller farmaceutisk acceptable salte heraf | |
| NZ236232A (en) | 1-aminoalkyl-4-naphthyl piperazine amide derivatives; preparation and pharmaceutical compositions thereof | |
| FI63566C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara dibenso(d g)(1,3,6)dioxazocin-derivat och av deras fysiologiskt godtagbara syraadditionssalter | |
| IE904719A1 (en) | Derivatives of 2-Aminopyrimidine-4-carboxamide, their preparation and therapeutic use | |
| EP0000220A1 (de) | Dihydrouracile, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
| FI63029B (fi) | Foerfarande foer framstaellning av ulcushaemmande n-substituerade 5,11-dihydro-(piperazin-1'-yl-alkanoyl)-6h-pyrido(2,3-b)(1,4)-benzodiazepin-6-on-derivater | |
| FI78909B (fi) | Foerfarande foer framstaellning av 2-piperazinylpyrimidinderivat anvaendbara som laekemedel. | |
| FI77456B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-/2-/4-(2-metoxifenyl) -1-piperazinyl/etyl/-2,4-(1h,3h)-kinazolindionderivat. | |
| FI62086B (fi) | Foerfarande foer framstaellning av bronkosekreterolytiska 5,11-dihydro-5h-pyrido-(2,3-b)(1,5)bensodiazepin-5-oner | |
| DE1720033A1 (de) | Neue Indolderivate und Verfahren zu ihrer Herstellung | |
| US6750223B2 (en) | 4-Anilino[2,3-b]quinoline derivatives, their preparation processes and pharmaceutical compositions comprising the same | |
| US3823155A (en) | Imidazoline derivatives with diuretic properties | |
| US4904688A (en) | Tricyclic amine derivatives | |
| US4994448A (en) | Condensed quinolinium and isoquinolinium derivatives | |
| US4016161A (en) | Amino-substituted 1,2,3,4,10,146-hexahydro-pyridino[1,2-a]dibenzo[c,f]azepines | |
| US4112105A (en) | Anti-inflammatory 3-(substituted-amino)-2,1-benzisothiazoles | |
| US4054572A (en) | Hexahydro pyridine [1,2d] dibenza [b,f] (1,4)-diazepines | |
| Augstein et al. | Adrenergic neurone blocking agents. III. Heterocyclic analogs of guanoxan | |
| FI61312B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 10-piperazinyl-dibenso-(b f)tiepinderivat | |
| Buzas et al. | Synthesis and psychoanaleptic properties of new compounds structurally related to diphenhydramine | |
| US3375248A (en) | Phenothiazine carboxylic acid derivatives | |
| DE2420168A1 (de) | Amino-substituierte piperidinderivate | |
| FI69074B (fi) | Foerfarande foer framstaellning av som psykotropiskt medel anvaendbar karbazolderivat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: EGYT GYOGYSZERVEGYESZETU GYAR |